NET ASSET VALUE – 31 May 2025
On the 31 May 2025 Flerie AB's Net Asset Value (NAV) was SEK 3,946 million and NAV per share was SEK 50.55.
|
Allocation of NAV |
Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Prokarium | 42% | 454 | 5.82 | 11.5% |
| Xspray Pharma | 18% | 209 | 2.68 | 5.3% |
| Empros Pharma | 79% | 204 | 2.62 | 5.2% |
| Atrogi | 44% | 197 | 2.52 | 5.0% |
| KAHR Medical | 31% | 181 | 2.32 | 4.6% |
| Lipum | 57% | 178 | 2.27 | 4.5% |
| Xintela | 61% | 156 | 2.00 | 4.0% |
| Microbiotica | 10% | 129 | 1.66 | 3.3% |
| Geneos Therapeutics | 12% | 92 | 1.18 | 2.3% |
| AnaCardio | 13% | 79 | 1.02 | 2.0% |
| Toleranzia | 53% | 64 | 0.82 | 1.6% |
| Mendus | 23% | 60 | 0.77 | 1.5% |
| EpiEndo Pharmaceuticals | 9% | 54 | 0.69 | 1.4% |
| Synerkine Pharma | 43% | 54 | 0.69 | 1.4% |
| Vitara Biomedical | 11% | 48 | 0.61 | 1.2% |
| Buzzard Pharmaceuticals | 14% | 32 | 0.40 | 0.8% |
| Sixera Pharma | 24% | 27 | 0.35 | 0.7% |
| Egetis Therapeutics | 2% | 20 | 0.25 | 0.5% |
| Alder Therapeutics | 21% | 17 | 0.22 | 0.4% |
| Amarna Therapeutics | 58% | 11 | 0.14 | 0.3% |
| Strike Pharma | 18% | 11 | 0.13 | 0.3% |
| Total | 2,277 | 29.17 | 57.7% | |
| Commercial Growth | ||||
| NorthX Biologics | 61% | 202 | 2.59 | 5.1% |
| Symcel | 30% | 192 | 2.46 | 4.9% |
| Chromafora | 30% | 73 | 0.93 | 1.8% |
| Nanologica | 43% | 42 | 0.54 | 1.1% |
| Frontier Biosolutions | 2% | 18 | 0.23 | 0.5% |
| Bohus Biotech | 45% | 17 | 0.21 | 0.4% |
| Total | 544 | 6.96 | 13.8% | |
| Limited Partnerships, total | 93 | 1.19 | 2.4% | |
| Assets related to Portfolio companies | 268 | 3.43 | 6.8% | |
| Other assets and liabilities | 765 | 9.79 | 19.4% | |
| Net asset value | 3,946 | 50.55 | 100.0% | |